https://doi.org/10.1002/pds.3522
H
Hrishikesh Kale
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
39
Papers
731
Citations
10
h-index
10
i10-index
Hrishikesh Kale is an academic researcher from Johnson & Johnson (United States). The author has contributed to research in topics: Opioid Use Disorder Treatment & Economic and Financial Impacts of Cancer & Acute Myeloid Leukemia Research. The author has an h-index of 10, co-authored 34 publications.
ORCID: 0000-0001-8571-1095Papers by this author
worksChanges in oxycodone and heroin exposures in the National Poison Data System after introduction of extended‐release oxycodone with abuse‐deterrent characteristics
2013 · Pharmacoepidemiology and Drug Safety · 124 citations
Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant
2021 · Advances in Therapy · 8 citations
https://doi.org/10.1007/s12325-021-01891-8
Association between anhedonia severity and clinical, humanistic, and economic outcomes among US adults with major depressive disorder
2025 · The International Journal of Neuropsychopharmacology · 3 citations
https://doi.org/10.1093/ijnp/pyaf048
Economic and clinical burden of major depressive disorder with insomnia symptoms in commercially and Medicaid-insured adults in the United States: A retrospective matched cohort study
2024 · Journal of Affective Disorders · 2 citations
https://doi.org/10.1016/j.jad.2024.12.048
Economic, clinical, and humanistic burden associated with major depressive disorder with prominent anhedonia in the United States: analysis of Medical Expenditure Panel Survey
2025 · Journal of Affective Disorders · 0 citations
https://doi.org/10.1016/j.jad.2025.120147
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat